Study of the Prevalence of Iron Deficiency in Patients With Heart Failure
CARENFER IC
1 other identifier
interventional
1,300
0 countries
N/A
Brief Summary
Despite its known prevalence in Heart Failure, a recent study conducted by Prof. Cacoub (unpublished) on the French national health insurance database showed that iron deficiency was a poorly diagnosed and poorly treated comorbidity. In chronic diseases including Heart Failure, Transferrin Saturation Factor is only performed in about 10% of cases while it is recommended for patients with Heart Failure (French Health High Authority 2011). The purpose of this study is to obtain current data on the prevalence of iron deficiency in France in patients with Heart Failure, applying the recommendations of European Society of Cardiology and French Health High Authority (determination of ferritinemia and Transferrin Saturation Factor).
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable heart-failure
Started May 2019
Shorter than P25 for not_applicable heart-failure
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
April 18, 2019
CompletedFirst Posted
Study publicly available on registry
April 23, 2019
CompletedStudy Start
First participant enrolled
May 15, 2019
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 30, 2019
CompletedStudy Completion
Last participant's last visit for all outcomes
June 30, 2019
CompletedApril 23, 2019
April 1, 2019
2 months
April 18, 2019
April 18, 2019
Conditions
Outcome Measures
Primary Outcomes (1)
Complete blood iron status
ferritin, Transferrin Saturation Factor
One day
Study Arms (1)
HEART FAILURE
EXPERIMENTALPatients with Heart Failure diagnosis
Interventions
Eligibility Criteria
You may qualify if:
- Patient, male or female, over 18 years of age
- Patient present at the hospital on the day of the study
- Diagnosis of Heart Failure (acute or chronic) regardless of left ventricular ejection fraction (LVEF)
- Patient with signed consent
You may not qualify if:
- Protected patient: major under guardianship, tutorship or other legal protection, deprived of liberty by judicial or administrative decision
- Pregnant or breastfeeding woman
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- VIFORFRANCElead
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- DIAGNOSTIC
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
April 18, 2019
First Posted
April 23, 2019
Study Start
May 15, 2019
Primary Completion
June 30, 2019
Study Completion
June 30, 2019
Last Updated
April 23, 2019
Record last verified: 2019-04
Data Sharing
- IPD Sharing
- Will not share